Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort

Documenti analoghi

• Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”
  Pubblicazione: (2026)
• Hyperphagia in Bardet–Biedl syndrome: Pathophysiology, burden, and management
  di: Philip L. Beales, et al.
  Pubblicazione: (2025)
• Clinical burden of hyperphagia, obesity and health outcomes in paediatric individuals with Bardet‐Biedl syndrome: A CRIBBS data analysis
  di: Jeremy Pomeroy, et al.
  Pubblicazione: (2025)
• Bardet‐Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction
  di: Jeremy W. Tomlinson
  Pubblicazione: (2024)
• Bardet‐Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best‐practice management
  di: Ashley Shoemaker
  Pubblicazione: (2024)